健康元(600380.SH):子公司LZ001片獲批開展臨牀試驗
格隆匯2月24日丨健康元(600380.SH)公佈,近日,健康元藥業集團股份有限公司控股子公司麗珠醫藥集團股份有限公司(簡稱:麗珠集團)收到國家藥品監督管理局下發的《藥物臨牀試驗批准通知書》(通知書編號:2022LP00260、2022LP00261),同意公司LZ001片開展臨牀試驗。
LZ001片是麗珠集團與浙江同源康醫藥股份有限公司合作研發的新一代抗耐藥性ROS1/NTRK/ALK多靶點抑制劑,作為新一代酪氨酸激酶抑制劑,對ROS1/NTRK/ALK等多個靶點顯示出優異的活性,能夠有效抑制各種耐藥基因突變,克服G2032R、G595R、G667C、G623R、G696A和G1202R等及潛在雙突變產生的耐藥性,有效解決諸多未滿足臨牀需求。LZ001片主要用於治療以非小細胞肺癌為主的ROS1/NTRK/ALK多靶點突變的實體瘤。
截至公吿披露日,LZ001累計直接投入的研發費用為人民幣3222.60萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.